{
    "clinical_study": {
        "@rank": "28600", 
        "arm_group": [
            {
                "arm_group_label": "Group A", 
                "arm_group_type": "Experimental", 
                "description": "Complement deficiecy"
            }, 
            {
                "arm_group_label": "Group B", 
                "arm_group_type": "Experimental", 
                "description": "asplenia/splenic dysfunction"
            }, 
            {
                "arm_group_label": "Group C", 
                "arm_group_type": "Active Comparator", 
                "description": "age-matched healthy controls"
            }
        ], 
        "brief_summary": {
            "textblock": "The study aims at evaluating the safety and immunogenicity of rMenB+OMV NZ when administered\n      to subjects from 2 to 17 years of age with increased risk of meningococcal disease because\n      either of primary or secondary complement deficiencies or of asplenia or splenic\n      dysfunction. A group of healthy age-matched subjects will be enrolled to serve as a\n      descriptive control for immunogenicity and safety."
        }, 
        "brief_title": "Safety and Immunogenicity of Novartis Meningococcal B Vaccine When Administered to Immunocompromised Children and Adolescents Compared to Healthy Subjects", 
        "completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Meningococcal Disease", 
        "condition_browse": {
            "mesh_term": "Meningococcal Infections"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Inclusion criterion applicable to ALL Groups\n\n          -  Subjects aged 2 to 17 years (inclusive) at enrollment\n\n          -  weighing at least 13 Kg at the time of enrollment\n\n        Inclusion criterion applicable to Group A - Subjects at risk of meningococcal disease\n        because of primary or secondary complement deficiencies\n\n        Inclusion criterion applicable to Group B\n\n        - Subjects at risk of meningococcal disease because of functional or anatomic asplenia\n\n        Inclusion criterion applicable to Group C - healthy subjects\n\n        Exclusion Criteria:\n\n        Exclusion criteria applicable to All Groups (A, B and C)\n\n          -  History of any previous immunization with a meningococcal B vaccine\n\n          -  History of severe allergic reaction after previous vaccinations, or hypersensitivity\n             to any component of the vaccine\n\n          -  Known HIV infection\n\n          -  History of any progressive or severe neurologic disorder or seizure disorder\n\n          -  Contraindication to intramuscular injection or blood drawn\n\n          -  Females who are pregnant, planning a pregnancy or nursing (breastfeeding)\n\n          -  Females of childbearing potential who have not used or do not plan to use acceptable\n             birth control measures\n\n          -  History or any illness/condition that, in the opinion of the investigator, might\n             interfere with the results of the study or pose additional risk to the subjects\n\n        Exclusion criterion applicable to Groups A and B\n\n        - Previous known or suspected disease caused by N. meningitidis in the last year.\n\n        Exclusion criteria applicable to Group C\n\n          -  Previous known or suspected disease caused by N. meningitidis\n\n          -  Known or suspected impairment/alteration of the immune system"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "17 Years", 
            "minimum_age": "2 Years"
        }, 
        "enrollment": {
            "#text": "150", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 15, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02141516", 
            "org_study_id": "V72_62", 
            "secondary_id": "2013-002454-78"
        }, 
        "intervention": [
            {
                "arm_group_label": "Group A", 
                "description": "2 doses of vaccine 2 months apart", 
                "intervention_name": "rMenB+OMV", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "Group B", 
                "description": "2 doses of vaccine 2 months apart", 
                "intervention_name": "rMenB+OMV", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "Group C", 
                "description": "2 doses of vaccine 2 months apart", 
                "intervention_name": "rMenB+OMV", 
                "intervention_type": "Biological"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Complement System Proteins"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Meningitis", 
            "vaccination", 
            "complement deficiency", 
            "asplenia", 
            "splenic dysfunction"
        ], 
        "lastchanged_date": "May 30, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Firenze", 
                        "country": "Italy", 
                        "zip": "50139"
                    }, 
                    "name": "12, Novartis Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Genova", 
                        "country": "Italy", 
                        "zip": "16132"
                    }, 
                    "name": "11, Novartis Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Milano", 
                        "country": "Italy", 
                        "zip": "20122"
                    }, 
                    "name": "10, Novartis Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Padova", 
                        "country": "Italy", 
                        "zip": "35128"
                    }, 
                    "name": "14, Novartis Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Roma", 
                        "country": "Italy", 
                        "zip": "00165"
                    }, 
                    "name": "13, Novartis Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Krakow", 
                        "country": "Poland", 
                        "zip": "31-302"
                    }, 
                    "name": "31, Novartis Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Warszawa", 
                        "country": "Poland", 
                        "zip": "04-730"
                    }, 
                    "name": "33, Novartis Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Wroclaw", 
                        "country": "Poland", 
                        "zip": "50-345"
                    }, 
                    "name": "30, Novartis Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Moscow", 
                        "country": "Russian Federation", 
                        "zip": "117997"
                    }, 
                    "name": "41, Novartis Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Moscow", 
                        "country": "Russian Federation", 
                        "zip": "117198"
                    }, 
                    "name": "42, Novartis Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Yekaterinburg", 
                        "country": "Russian Federation", 
                        "zip": "620149"
                    }, 
                    "name": "43, Novartis Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Barcelona", 
                        "country": "Spain", 
                        "zip": "08035"
                    }, 
                    "name": "21, Novartis Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain", 
                        "zip": "46026"
                    }, 
                    "name": "23, Novartis Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain", 
                        "zip": "28046"
                    }, 
                    "name": "22, Novartis Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Santiago De Compostela", 
                        "country": "Spain", 
                        "zip": "15706"
                    }, 
                    "name": "20, Novartis Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Valencia", 
                        "country": "Spain", 
                        "zip": "46026"
                    }, 
                    "name": "24, Novartis Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Italy", 
                "Poland", 
                "Russian Federation", 
                "Spain"
            ]
        }, 
        "number_of_arms": "3", 
        "official_title": "A Phase IIIb, Open Label, Controlled, Multi-Center Study to Evaluate the Safety, Tolerability and Immunogenicity of Two Doses of Novartis Meningococcal Group B Vaccine When Administered to Immunocompromised Patients From 2 to 17 Years of Age Who Are at Increased Risk of Meningococcal Disease Because of Complement Deficiency or Asplenia Compared to Matched Healthy Controls", 
        "overall_contact": {
            "last_name": "Novartis Drug Information Services", 
            "phone": "+1 800 244 7668"
        }, 
        "overall_official": {
            "affiliation": "Novartis Vaccines", 
            "last_name": "Novartis Vaccines", 
            "role": "Study Chair"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Spain: Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios", 
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
                "Russia: Ministry of Health of Russian Federation", 
                "Italy: AIFA", 
                "Poland: URPL"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "To evaluate the immunogenicity of two doses of rMenB+OMV NZ in subjects with increased risk of meningococcal disease because of complement deficiency or asplenia and in healthy age-matched subjects, at 1 month after the second vaccination.", 
                "measure": "hSBA GMT, GMR, percentage of subjects with hSBA titers \u22655 and \u2265 8 against serogroups B indicator strains and ELISA GMC, GMR for vaccine antigen 287-953", 
                "safety_issue": "No", 
                "time_frame": "30 days after 2nd vaccination"
            }, 
            {
                "measure": "percentage of subject with four-fold increase in hSBA titers against serogroups B indicator strains and in ELISA concentration for vaccine antigen 287-953", 
                "safety_issue": "No", 
                "time_frame": "30 days after 2nd vaccination"
            }, 
            {
                "description": "To assess the safety and tolerability of two doses of rMenB+OMV NZ in subjects with increased risk of meningococcal disease because of complement deficiency or asplenia and in healthy age-matched subjects", 
                "measure": "Frequencies and percentage of subjects with solicited AE unsolicited AE, medically attended AEs, AEs leading to withdrawn and SAEs", 
                "safety_issue": "Yes", 
                "time_frame": "participants will be followed for the duration of study, within an expected average of  3 months"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02141516"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Novartis", 
        "sponsors": {
            "collaborator": {
                "agency": "Novartis Vaccines", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Novartis", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}